Baird Have Target Price $20 on Natera (NASDAQ:NTRA). Researchers Didn’t Change firms “Outperform” rating.

June 29, 2018 - By Carey Conley

Natera, Inc. (NASDAQ:NTRA) Corporate Logo

Reiterated Natera (NASDAQ:NTRA) Rating.

In a report sent to investors by Baird’s research professionals, Natera (NASDAQ:NTRA) had it’s stock Rating maintained to “Outperform”. On Thursday morning it has $20 or 4.22 % TP that means a potential upside move.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

In total 4 analysts cover Natera (NASDAQ:NTRA). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 8 are the (NASDAQ:NTRA)’s analyst reports since March 14, 2018 according to StockzIntelligence Inc. On Monday, June 25 the firm has “Overweight” rating given by Morgan Stanley. The stock rating was maintained by Robert W. Baird with “Buy” on Wednesday, March 14. On Wednesday, May 9 the rating was maintained by Morgan Stanley with “Overweight”. On Wednesday, March 14 Canaccord Genuity maintained Natera, Inc. (NASDAQ:NTRA) with “Buy” rating. On Monday, June 25 the company was maintained by Canaccord Genuity. On Friday, June 22 the rating was maintained by Craig Hallum with “Buy”. On Thursday, June 28 Robert W. Baird maintained Natera, Inc. (NASDAQ:NTRA) with “Outperform” rating.

The stock increased 1.16% or $0.22 during the last trading session, hitting $19.19.Currently Natera, Inc. is uptrending after 12.60% change in last June 29, 2017. NTRA has 209,466 shares volume. NTRA outperformed the S&P500 by 0.03%.

On August, 14 WallStreet expected Natera, Inc. (NASDAQ:NTRA)’s earnings release, as reported by RTT. Analysts predict 1.92 % diference or $-0.53 from the $-0.52 EPS from 2017. Wall Street now sees -13.11 % EPS growth despite Natera, Inc. last quarter’s EPS of $-0.61.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services.The firm is valued at $1.05 billion. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.Currently it has negative earnings. The firm also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

For more Natera, Inc. (NASDAQ:NTRA) news published recently go to: Fool.com, Seekingalpha.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Why Natera Inc. Is Rising Today” published on June 25, 2018, “Key events next week – healthcare” on June 21, 2018, “42 Biggest Movers From Yesterday” with a publish date: June 28, 2018, “40 Stocks Moving In Wednesday’s Mid-Day Session” and the last “44 Biggest Movers From Yesterday” with publication date: June 26, 2018.

Natera, Inc. (NASDAQ:NTRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.